WilmerHale Advises Argos Therapeutics in Asset Sale to Affiliate of SCM Lifescience and Genexine

Download IconDownload Print IconPrint

WilmerHale Advises Argos Therapeutics in Asset Sale to Affiliate of SCM Lifescience and Genexine

Client News

Related Solutions

WilmerHale has been at the forefront of complex financial restructuring and bankruptcy litigation and policy matters for decades.
Advising life sciences innovators, investors and industry leaders on complex transactions, legal issues and business challenges.
WilmerHale lawyers have decades of experience advising public and private companies in all aspects of mergers and acquisitions.
A deep and diverse practice focused on maximizing tax efficiencies and minimizing tax risks for clients nationally and internationally.

WilmerHale acted as lead counsel to immunotherapy company Argos Therapeutics, Inc. (OTCPK: ARGS.Q) in the sale of substantially all of its assets to an affiliate of SCM Lifescience Co., Ltd. and Genexine, Inc.

After two decades of refining its technology, Argos faced liquidity challenges in continuing its intellectual property development mission. In order to preserve the value of its assets, Argos filed for Chapter 11 bankruptcy in the District of Delaware in November 2018. Argos immediately sought to sell its assets to a stalking horse buyer, or any higher and better bidder, pursuant to a Bankruptcy Code section 363 sale process. As a result of a January 2019 auction lasting 26 rounds, Argos tripled the sale price for its assets and closed its sale transaction in February 2019.

The WilmerHale team representing Argos in the transaction included George Shuster, Lauren Lifland, and Stuart Falber, with tax law assistance from Robert Burke. Lead bankruptcy counsel for Argos is the Delaware firm Landis, Rath & Cobb LLP.


Notice

Unless you are an existing client, before communicating with WilmerHale by e-mail (or otherwise), please read the Disclaimer referenced by this link.(The Disclaimer is also accessible from the opening of this website). As noted therein, until you have received from us a written statement that we represent you in a particular manner (an "engagement letter") you should not send to us any confidential information about any such matter. After we have undertaken representation of you concerning a matter, you will be our client, and we may thereafter exchange confidential information freely.

Thank you for your interest in WilmerHale.

I Accept Cancel